Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action

OBJECTIVESTo investigate the relative roles of angiotensin II, bradykinin, and calcium-dependent pathways in the genesis of mesenteric vascular hypertrophy in experimental diabetes. DESIGNStreptozotocin-induced diabetic Sprague–Dawley rats were randomly allocated to these treatments for 24 weeksno t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hypertension 1998-06, Vol.16 (6), p.793-799
Hauptverfasser:	Cao, Zemin, Hulthén, U Lennart, Allen, Terri J, Cooper, Mark E
Format:	Artikel
Sprache:	eng
Schlagworte:	Actins - metabolism Angiotensin-Converting Enzyme Inhibitors - pharmacology Animals Antihypertensive agents Benzimidazoles - pharmacology Biological and medical sciences Blood Pressure - drug effects Calcium Channel Blockers - pharmacology Calcium Channels - drug effects Calcium Channels - metabolism Cardiovascular system Diabetes Mellitus, Experimental - metabolism Diabetes Mellitus, Experimental - pathology Diabetes Mellitus, Experimental - physiopathology Dihydropyridines - pharmacology Hypertrophy Male Medical sciences Mesenteric Arteries - drug effects Mesenteric Arteries - pathology Mibefradil Muscle, Smooth, Vascular - drug effects Muscle, Smooth, Vascular - pathology Peptidyl-Dipeptidase A - drug effects Peptidyl-Dipeptidase A - metabolism Pharmacology. Drug treatments Ramipril - pharmacology Random Allocation Rats Rats, Sprague-Dawley Tetrahydronaphthalenes - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!